IDEMIA
10.2.2020 08:51:07 CET | Business Wire | Press release
FCA takes its forward-thinking global telematics program to the next level with the integration of IDEMIA’s eSIM (DAKOTA) and Subscription Manager platform (Smart Connect). These groundbreaking services, already operational, are enabling each day FCA to optimize vehicle operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200209005062/en/
The DAKOTA eSIM will be embedded directly into new FCA vehicle models that will be launched in multiple regions. Combined with Smart Connect, this solution gives the automaker the flexibility to dynamically choose the best connectivity provider throughout the lifetime of the vehicle on a worldwide scale.
IDEMIA’s solutions not only pave the way for in-demand services such as emergency calls, predictive maintenance and insurance-related services, but also simplify the manufacturing process and provide the capability to remotely update software and tailor connectivity packages to local regulations and requirements.
As connected cars are expected to account for more than 90% of overall vehicle sales by 2024 and the value of in-car connected services is set to jump 28% between 2017 and 2030, the market is primed for DAKOTA and Smart Connect.
“As the number of connected cars is soaring, our partnership with FCA showcases our high-tech expertise and know-how. The fact that leading premium car makers and more than 500 mobile operators around the world turn to IDEMIA to support them in addressing various connectivity needs and simplify the migration to this new ecosystem, shows that we are clearly a trusted partner,” stated Yves Portalier, Executive Vice President for Biometric Devices & Automotive activities at IDEMIA.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 13,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, head to www.idemia.com / Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20200209005062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
teamLab Borderless in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries6.8.2026 13:07:00 CEST | Press release
Approximately 1 in every 12 travelers from the United States and 1 in every 9 travelers from Australia visiting Japan visit teamLab Borderless teamLab Borderless: MORI Building DIGITAL ART MUSEUM (teamLab Borderless) in Tokyo has welcomed over 4 Million visitors as of July 31, 2026, approximately 2 years and 5 months since its opening.*1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806672709/en/ teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries These visitors arrived from more than 185 countries and regions. International visitors account for approximately 70% of the total number. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom and Germany. Among those who visited Japan between February 2024 and June 2026, approximately 1 in every 12 travelers from t
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 20266.8.2026 13:00:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under eva
Verdane Partners With Factbird to Accelerate Its Global Leadership Position in Manufacturing Intelligence6.8.2026 12:53:00 CEST | Press release
Verdane, the European specialist growth buyout investment firm, today announced a partnership and strategic majority investment in Factbird, a leading Danish IoT and recurring software company providing manufacturing intelligence solutions. The existing investors, Expedition Growth Capital and EIFO, are reinvesting significantly alongside Verdane. Factbird’s hardware-enabled software solutions help industrial businesses to improve productivity, reduce downtime and make more informed operational decisions that help manufacturers to gather, manage, analyse and act on production data to improve efficiency and reduce waste. Factbird’s customers experience increased production capacity and increased revenue leading to a very high return on investment that often lead to multi-million-dollar improvements. The company serves more than 300 customers including many global blue-chip customers and has established a global leadership position within digital manufacturing and industrial software int
Purina Named as First Publicly Announced NIQ ConnectAI Charter Client6.8.2026 12:45:00 CEST | Press release
Purina is among the first companies working with NIQ forward-deployed engineers to bring consumer intelligence into enterprise AI workflowsFive global companies have joined the ConnectAI Charter Program, with individual client announcements and case studies to follow across personal care, pet care, beauty and beverages NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today named Purina as the first publicly announced client in its ConnectAI Charter Program. The announcement follows NIQ’s launch of the program with five global organizations across personal care, pet care, beauty and beverages, with additional client announcements and case studies expected as engagements advance. Through ConnectAI, NIQ forward-deployed engineers and data scientists are working within Purina’s technology environment to explore how NIQ consumer and market intelligence can support everyday AI-enabled workstreams and help teams access relevant insights more efficiently. "Understanding the nee
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom